- Home
- BCAX vs CAPR Comparison
BCAX vs CAPR Comparison
Compare BCAX & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAX
- CAPR
- Stock Information
- Founded
- BCAX 2018
- CAPR 2005
- Country
- BCAX United States
- CAPR United States
- Employees
- BCAX N/A
- CAPR N/A
- Industry
- BCAX
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAX
- CAPR Health Care
- Exchange
- BCAX NYSE
- CAPR Nasdaq
- Market Cap
- BCAX 670.9M
- CAPR 600.7M
- IPO Year
- BCAX 2024
- CAPR N/A
- Fundamental
- Price
- BCAX $9.32
- CAPR $8.26
- Analyst Decision
- BCAX Strong Buy
- CAPR Strong Buy
- Analyst Count
- BCAX 7
- CAPR 7
- Target Price
- BCAX $29.17
- CAPR $40.14
- AVG Volume (30 Days)
- BCAX 1.4M
- CAPR 2.6M
- Earning Date
- BCAX 08-16-2025
- CAPR 08-06-2025
- Dividend Yield
- BCAX N/A
- CAPR N/A
- EPS Growth
- BCAX N/A
- CAPR N/A
- EPS
- BCAX N/A
- CAPR N/A
- Revenue
- BCAX N/A
- CAPR $17,363,588.00
- Revenue This Year
- BCAX N/A
- CAPR $258.96
- Revenue Next Year
- BCAX N/A
- CAPR $8.02
- P/E Ratio
- BCAX N/A
- CAPR N/A
- Revenue Growth
- BCAX N/A
- CAPR N/A
- 52 Week Low
- BCAX $7.80
- CAPR $3.52
- 52 Week High
- BCAX $28.09
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- BCAX N/A
- CAPR 36.50
- Support Level
- BCAX N/A
- CAPR $11.57
- Resistance Level
- BCAX N/A
- CAPR $13.51
- Average True Range (ATR)
- BCAX 0.00
- CAPR 1.70
- MACD
- BCAX 0.00
- CAPR -0.33
- Stochastic Oscillator
- BCAX 0.00
- CAPR 24.52
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.